Paosonelle (Drospirenone, Estradiol Hemihydrate)

Drospirenone, the active ingredient in Paosonelle, is a combined hormonal contraceptive presented as a tablet for oral use. It treats hormonal imbalances and related conditions in women of reproductive age. GNH USA supplies Paosonelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Paosonelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paosonelle, a combined estrogen‑progestin preparation, is used in hormone‑replacement therapy pathways.

- Menopause symptom relief: Improves vasomotor symptoms and prevents bone loss. - Hypo‑estrogenism due to ovarian insufficiency: Restores estrogen levels and alleviates related symptoms. - Contraception: Provides reliable prevention of pregnancy when taken as directed.

Adverse reactions may occur with any hormonal product. Monitoring and patient education are essential.

Common Side Effects: - Nausea - Headache - Breast tenderness - Weight gain - Mood changes - Irregular vaginal bleeding

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Stroke - Myocardial infarction - Severe allergic reaction (anaphylaxis) - Hepatotoxicity

When prescribing Paosonelle, clinicians should consider several safety aspects.

- Thromboembolic risk: Assess patient history of clotting disorders. - Cardiovascular health: Evaluate blood pressure and lipid profile. - Liver function: Monitor hepatic enzymes in patients with liver disease. - Smoking status: Advise against use in smokers over 35 years old. - Pregnancy and lactation: Contraindicated during pregnancy and breastfeeding. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Paosonelle can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers:   - Strong   -  

Moderate  :

-